BioPharma Resources

Drug Trial Radar · NCT07917754

A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)

A Phase 2/3 Multi-arm, Open-label Study of MK-1045 in Combination With Zilovertamab Vedotin in Participants With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 470 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

470

Planned (sponsor's estimate)

Start

Dec 13, 2026

Primary completion

Mar 13, 2037

Study completion Mar 13, 2037

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat relapsed or refractory, diffuse large B-cell lymphoma (R/R DLBCL). Relapsed means the cancer came back after treatment. Refractory means the number of cancer cells in the body did not go down or the cancer did not go away after treatment. Researchers want to learn if MK-1045, an immunotherapy, can treat R/R DLBCL when given with zilovertamab vedotin (ZV), a type of targeted therapy. The goals of this trial are to learn: * About the safety of MK-1045 and ZV and if participants tolerate them together. To tolerate these drugs together means that participants will receive the trial medicines unless they need to stop them due to health problems * About the number of participants whose cancer responds (gets smaller or goes away) to treatment with MK-1045 and ZV * If participants who receive MK-1045 and ZV live longer without the cancer growing or spreading compared to participants who receive standard treatments

Conditions

  • Lymphoma, Large B-Cell, Diffuse
  • Diffuse Large B-Cell Lymphoma

Interventions

  • MK-1045Biological

    Intravenous (IV) administration

  • Zilovertamab vedotinBiological

    1.5 or 1.75 mg/kg administered IV

  • RituximabBiological

    375mg/m\^2, administered IV

  • Rituximab biosimilarBiological

    375 mg/m\^2, administered IV

  • Polatuzumab vedotinBiological

    1.8 mg/kg, administered IV

  • BendamustineDrug

    90 mg/m\^2, administered IV for 2 consecutive days

  • LenalidomideBiological

    25 mg, administered orally

  • TafasitamabBiological

    12 mg/kg, administered IV, on Days 1, 4, 8, 15, and 22 for Cycle 1; Days 1, 8, 15, and 22 for Cycles 2 and 3; Days 1 and 15 for Cycles 4 to 12 (each Cycle is 28 days). After Cycle 12, administered once every 2 weeks

  • Rescue Medication - BiologicalBiological

    Participants may receive Tocilizumab (or biosimilar) after administration of MK-1045 in the event of cytokine release syndrome

  • Rescue Medications - DrugDrug

    Participants may receive the following rescue medications before administration of MK-1045: acetaminophen (or similar), diphenhydramine (or similar antihistamine), dexamethasone, Varicellazoster/herpes simplex virus prophylaxis (acyclovir, valacyclovir, famiciclovir), and pneumocystis jirovecii pneumonia prophylaxis (trimethoprim/sulfamethoxazole, dapsone, atovaquone, pentamidine).

  • Granulocyte-colony stimulating factor (G-CSF)Other

    Given as prophylaxis as listed in the National comprehensive Cancer Network guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1A: Number of Participants Who Experience Dose Limiting Toxicity (DLT)Time frame: Up to approximately 42 days
  2. Part 1A and 1B: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 53 months
  3. Part 1A and 1B: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 11 months
  4. Part 1B: Objective Response Rate (ORR)Time frame: Up to approximately 53 months
  5. Part 2: Progression Free Survival (PFS)Time frame: Up to approximately 53 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.